Cooperative Agreement 2P2CMS332032
Award Date 8/1/25
Completion Date 12/31/35
Dollars Obligated $75K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Vermont, USA
Similar Awards
- The Department of Social Services Connecticut was awarded a $7,404,199 Cooperative Agreement by the Centers for Medicare and Medicaid Services under the Cell and Gene Therapy (CGT) Access Model (CFDA 93.885) to increase access to cell and gene therapy for Medicaid members with sickle cell disease in Connecticut. Key activities include: Developing educational materials and raising awareness about cell and gene therapies through collaborations with a community-based organization and four...
- The Mississippi Division of Medicaid (DOM) was awarded a $4,912,944 Cooperative Agreement from the Centers for Medicare and Medicaid Services (CFDA 93.885 - Cell and Gene Therapy (CGT) Access Model) to transform healthcare for Medicaid beneficiaries living with sickle cell disease. The funding will support five key initiatives over a 10-year period from August 2025 to December 2035: 1) Travel support for patients and caregivers to access treatment, 2) Individualized care coordination to guide...
- The Rhode Island Executive Office of Health and Human Services (EOHHS) was awarded a $793,419.04 Cooperative Agreement under the Centers for Medicare and Medicaid Services' (CMS) Cell and Gene Therapy (CGT) Access Model federal grant program (CFDA 93.885). The funding will be used to enhance access to cell and gene therapies and improve care for individuals with sickle cell disease in Rhode Island through a comprehensive, multi-faceted approach. Key activities include developing evidence-based...
- The North Carolina Department of Health and Human Services (NC DHHS) was awarded a $558,941 cooperative agreement from the Centers for Medicare and Medicaid Services (CMS) under the Cell and Gene Therapy (CGT) Access Model program (CFDA 93.885). The funding will support a set of activities aimed at ensuring the successful implementation of the CGT Access Model in North Carolina, with the overarching goal of strengthening the state's capacity to provide access to cell and gene therapies for...
- The Pennsylvania Department of Human Services (DHS) was awarded a $794,800 Cooperative Agreement from the Centers for Medicare and Medicaid Services (CMS) under the federal Cell and Gene Therapy (CGT) Access Model program (CFDA 93.885). The funding will be used to provide additional services, education, and supports for Medicaid beneficiaries who may be candidates for sickle cell disease gene therapy. DHS will collaborate with the Pennsylvania Department of Health's Sickle Cell Disease...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...
- The Department of Health Care Finance (DHCF), the District of Columbia's state Medicaid agency, was awarded a $7,072,261 cooperative agreement by the Centers for Medicare and Medicaid Services (CFDA #93.885 Cell and Gene Therapy (CGT) Access Model) on August 1, 2025. The funding will support DHCF's implementation of the CGT Access Model, which aims to improve access to cell and gene therapies, particularly for sickle cell disease patients. The grant will enable DHCF to: 1) build internal...
- The Illinois Department of Healthcare and Family Services (HFS) was awarded a $794,800 Cooperative Agreement under the Centers for Medicare and Medicaid Services' (CMS) Cell and Gene Therapy (CGT) Access Model (CFDA 93.885). The award will fund HFS staff to implement the CGT Access Model, conduct research to evaluate Medicaid customer access to sickle cell disease CGTs and the effectiveness of wraparound services, and support Community-Based Organizations (CBOs) to provide education,...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), will support the development of a mathematical model to study the oxygen-dependent equilibrium solubility of sickle hemoglobin in single red blood cells. The $719,128 award has an ultimate completion date of May 31, 2029 and aims to address the unmet need for mechanistic models of...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research CFDA program (93.837), awarded a $483,852 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a platform technology for measuring the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This technology aims to support drug potency assessment and patient risk stratification for sickle...